Redeye ceases its coverage of Lipum and will not provide research on the company following the completion of the merger between Flerie and L...
Redeye comments on Lipum’s announcement that the Swedish Companies Registration Office has approved the planned merger with Flerie.
Redeye leaves a comment following Lipum’s announcement that it has been selected, pending final negotiations, to lead a European consortium ...
Redeye provides a research update following the recently published Q4 report from Lipum.
Redeye provides a research update following the recently published Q3 report from Lipum.
Lipum and Flerie have agreed to merge in a transaction that will see Lipum absorbed into Flerie in exchange for newly issued Flerie shares, ...
Lipum has presented new topline data from collaborative studies with Linköping University that strengthen the scientific foundation for SOL-...
Redeye provides a research update following the Q2 report published by Lipum earlier today.
Redeye provides a research update following the Q1 report published by Lipum earlier today.
Redeye comments on Lipum’s announcement of the finalized Clinical Study Report (CSR) for the phase I trial with lead candidate SOL-116.
Redeye provides a research update following the Q4 report published by Lipum earlier today.
Redeye leaves a comment following Lipum’s announcement of positive top-line results from the phase I clinical trial with its lead candidate ...
Redeye leaves a comment following Lipum’s announcement of a grant from Eurostars.
Redeye provides a research update following the Q3 report published by Lipum earlier today.
Redeye leaves a comment following Lipum’s announcement of further clinical advancements in the ongoing phase I study with lead candidate SOL...
Redeye leaves a short comment following Lipum’s announcement of a loan commitment of SEK20m with Flerie Invest.
Redeye provides a research update following Lipum’s clinical progress, recent rights issue, and revised development plan for SOL-116.
Redeye leaves a comment following the yesterday’s press release of the preliminary outcome of Lipum’s recent rights issue.
Redeye leaves a comment following Flerie Invest’s mandatory offer of SEK6.
Redeye provides a research update on Lipum following the Q4 report published by the company earlier today.
Redeye is encouraged to learn that Lipum’s lead candidate, SOL-116, has shown favorable safety and tolerability in the first part of the pha...
Redeye leaves a comment on today’s news that Einar Pontén is stepping down as the CEO of Lipum and that the Board has decided to appoint Ola...
Redeye provides a research update on Lipum following the Q3 report published by the company earlier today.
Redeye provides a research update on Lipum following the Q2 report published by the company earlier today.
Redeye leaves a comment following Lipum’s announcement of the preliminary outcome of the rights issue.
Redeye leaves a comment following Lipum’s announcement of an upcoming rights issue of up to 2,870,334 shares at a subscription price of SEK9...
Redeye provides a research update on Lipum following the Q1 report published by the company earlier today.
Redeye leaves a comment on the Q3 report published by Lipum earlier this morning.
Redeye leaves a comment following Lipum’s announcement of phase I trial initiation with SOL-116.
Redeye leaves a short comment following Lipum’s announcement yesterday regarding the outcome of the previously communicated directed share i...
Redeye leaves a short comment on Lipum’s announcement of a CTA approval for the phase I trial with SOL-116.
Redeye leaves a comment following Lipum’s announcement yesterday evening of a directed share issue of approximately SEK 39m.
Redeye leaves a comment on the Q2 report published by Lipum earlier this morning.
Redeye initiates coverage of Lipum, a Swedish biotech company offering a unique approach to the USD 60 billion-plus inflammatory diseases ma...
